Home » Stocks » SRDX

SurModics, Inc. (SRDX)

Stock Price: $58.19 USD -0.96 (-1.62%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 800.44M
Revenue (ttm) 94.55M
Net Income (ttm) 701,000
Shares Out 13.67M
EPS (ttm) 0.05
PE Ratio 1,163.80
Forward PE 161.29
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $58.19
Previous Close $59.15
Change ($) -0.96
Change (%) -1.62%
Day's Open 59.71
Day's Range 57.65 - 60.00
Day's Volume 24,341
52-Week Range 33.45 - 60.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PAHC vs. SRDX: Which Stock Is the Better Value Option?

Other stocks mentioned: PAHC
1 week ago - Zacks Investment Research

Let's take a look at the three MedTech stocks performing well lately, banking on a host of impressive developments.

Other stocks mentioned: HRC, OMI, PKI
2 weeks ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Access--Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices

2 weeks ago - Business Wire

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Present at Sidoti & Company Virtual Investor Conference Thursday, March 25, at 10:00 a.m. (ET)

1 month ago - Business Wire

Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.

1 month ago - Zacks Investment Research

Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.

2 months ago - Zacks Investment Research

SurModics (SRDX) delivered earnings and revenue surprises of 133.33% and -3.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Surmodics (NASDAQ:SRDX) rose 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 60.00% over the past year to $0.02, which beat the esti...

2 months ago - Benzinga

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports First Quarter Fiscal 2021 Results

2 months ago - Business Wire

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Host Virtual Annual Meeting of Shareholders on February 11 at 4:00 p.m. (CT)

2 months ago - Business Wire

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Webcast First Quarter Fiscal 2021 Earnings Conference Call on February 9.

2 months ago - Business Wire

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #DCB--12-Month Data from Surmodics' TRANSCEND Trial Presented at LINC 2021. SurVeil™ Drug-Coated Balloon (DCB) demonstrates non-inferior safety and efficacy

2 months ago - Business Wire

PAHC vs. SRDX: Which Stock Is the Better Value Option?

Other stocks mentioned: PAHC
2 months ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Announces TRANSCEND Trial 12-Month Data to be Presented at LINC 2021 Virtual Event.

3 months ago - Business Wire

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Avess--Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020; Study finds 100 percent target lesion patency at 30 days.

5 months ago - Business Wire

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: ANIP, SRGA, VNDA, PETS
5 months ago - GuruFocus

Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.

5 months ago - Zacks Investment Research

Surmodics, Inc.'s (SRDX) CEO Gary Maharaj on Q4 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SurModics (SRDX) delivered earnings and revenue surprises of -1900.00% and 4.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports Fourth Quarter Fiscal 2020 Results

5 months ago - Business Wire

Surmodics is in the early stages of an extended growth period in our view, with high conversion potential from their pipeline. The company has key differentiators within its medical devices and IVD segm...

5 months ago - Seeking Alpha

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics, Inc. (Nasdaq: SRDX), to webcast Fourth quarter fiscal 2020 earnings in a conference call on November 4, 2020.

5 months ago - Business Wire

NUVA vs. SRDX: Which Stock Is the Better Value Option?

Other stocks mentioned: NUVA
6 months ago - Zacks Investment Research

The FDA clearance of Surmodics' (SRDX) Pounce Thrombus Retrieval System will bolster the current treatment of complex PAD.

6 months ago - Zacks Investment Research

Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.

Other stocks mentioned: HCA, QGEN
6 months ago - Zacks Investment Research

Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.

7 months ago - Zacks Investment Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.

8 months ago - Zacks Investment Research

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SurModics (SRDX) delivered earnings and revenue surprises of 110.00% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #FDAClearance--Surmodics receives FDA 510(k) clearance for Sublime™ Radial Access 0.014 RX PTA Dilatation Catheter.

8 months ago - Business Wire

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports Third Quarter Fiscal 2020 Results and will hold a webcast conference call at 4 pm CT.

8 months ago - Business Wire

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics issues an earnings release after market closes and will host a webcast of fiscal 2020 third-quarter conference call on August 5 at 4 pm CT.

8 months ago - Business Wire

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for June 29th

Other stocks mentioned: BEN, SPWH, ZS
9 months ago - Zacks Investment Research

Surmodics (SRDX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

9 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for June 26th 2020

Other stocks mentioned: CMC, HEAR, RIO
9 months ago - Zacks Investment Research

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

10 months ago - Zacks Investment Research

Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.

10 months ago - Zacks Investment Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

11 months ago - Zacks Investment Research

Surmodics' (SRDX) CEO Gary Maharaj on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SurModics (SRDX) delivered earnings and revenue surprises of 180.00% and 1.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

1 year ago - Zacks Investment Research

About SRDX

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologi... [Read more...]

Industry
Diagnostics & Research
IPO Date
Mar 4, 1998
CEO
Gary Maharaj
Employees
370
Stock Exchange
NASDAQ
Ticker Symbol
SRDX
Full Company Profile

Financial Performance

In 2020, SurModics's revenue was $94.86 million, a decrease of -5.21% compared to the previous year's $100.08 million. Earnings were $1.12 million, a decrease of -85.21%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SurModics stock is "Buy." The 12-month stock price forecast is 70.75, which is an increase of 21.58% from the latest price.

Price Target
$70.75
(21.58% upside)
Analyst Consensus: Buy